Pharsight

Drugs that contain Testosterone

1. Androgel patents expiration

ANDROGEL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9132089 BESINS HLTHCARE Pharmaceutical composition and method for treating hypogonadism
Aug, 2020

(3 years ago)

US9125816 BESINS HLTHCARE Pharmaceutical composition and method for treating hypogonadism
Aug, 2020

(3 years ago)

US6503894 BESINS HLTHCARE Pharmaceutical composition and method for treating hypogonadism
Aug, 2020

(3 years ago)

US6503894

(Pediatric)

BESINS HLTHCARE Pharmaceutical composition and method for treating hypogonadism
Mar, 2021

(3 years ago)

US9132089

(Pediatric)

BESINS HLTHCARE Pharmaceutical composition and method for treating hypogonadism
Mar, 2021

(3 years ago)

US9125816

(Pediatric)

BESINS HLTHCARE Pharmaceutical composition and method for treating hypogonadism
Mar, 2021

(3 years ago)

US8486925 BESINS HLTHCARE Testosterone gel and method of use
Oct, 2026

(2 years from now)

US8466136 BESINS HLTHCARE Testosterone gel and method of use
Oct, 2026

(2 years from now)

US8446138 BESINS HLTHCARE Stability compensation circuit and DC-DC converter including the same
Oct, 2026

(2 years from now)

US8466137 BESINS HLTHCARE Testosterone gel and method of use
Oct, 2026

(2 years from now)

US8754070 BESINS HLTHCARE Testosterone gel and method of use
Oct, 2026

(2 years from now)

US8729057 BESINS HLTHCARE Testosterone gel and method of use
Oct, 2026

(2 years from now)

US8759329 BESINS HLTHCARE Testosterone gel and method of use
Oct, 2026

(2 years from now)

US8466138 BESINS HLTHCARE Testosterone gel and method of use
Oct, 2026

(2 years from now)

US8741881 BESINS HLTHCARE Testosterone gel and method of use
Oct, 2026

(2 years from now)

Market Authorisation Date: 26 September, 2003

Treatment: Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone

Dosage: GEL;TRANSDERMAL; GEL, METERED;TRANSDERMAL

More Information on Dosage

ANDROGEL family patents

Family Patents

2. Axiron patents expiration

AXIRON's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6299900 ELI LILLY AND CO Dermal penetration enhancers and drug delivery systems involving same
Feb, 2017

(7 years ago)

US6818226 ELI LILLY AND CO Dermal penetration enhancers and drug delivery systems involving same
Feb, 2017

(7 years ago)

US8071075 ELI LILLY AND CO Dermal penetration enhancers and drug delivery systems involving the same
Feb, 2017

(7 years ago)

US6923983 ELI LILLY AND CO Transdermal delivery of hormones
Feb, 2017

(7 years ago)

US8784878 ELI LILLY AND CO Transdermal delivery rate control using amorphous pharmaceutical compositions
Jul, 2023

(11 months ago)

US8993520 ELI LILLY AND CO Method and composition for transdermal drug delivery
Jun, 2026

(1 year, 11 months from now)

US9180194 ELI LILLY AND CO Method and composition for transdermal drug delivery
Jun, 2026

(1 year, 11 months from now)

US8807861 ELI LILLY AND CO Spreading implement
Feb, 2027

(2 years from now)

US9289586 ELI LILLY AND CO Spreading implement
Feb, 2027

(2 years from now)

US8419307 ELI LILLY AND CO Spreading implement
Feb, 2027

(2 years from now)

US8435944 ELI LILLY AND CO Method and composition for transdermal drug delivery
Sep, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 23, 2013

Market Authorisation Date: 23 November, 2010

Treatment: Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone; A method of transdermally delivering testosterone; A method of increasing t...

Dosage: SOLUTION, METERED;TRANSDERMAL

How can I launch a generic of AXIRON before it's drug patent expiration?
More Information on Dosage

AXIRON family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Fortesta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6319913 ENDO PHARMS Penetration enhancing and irritation reducing systems
Nov, 2018

(5 years ago)

US6579865 ENDO PHARMS Penetration enhancing and irritation reducing systems
Nov, 2018

(5 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 29, 2013

Market Authorisation Date: 29 December, 2010

Treatment: Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone

Dosage: GEL, METERED;TRANSDERMAL

How can I launch a generic of FORTESTA before it's drug patent expiration?
More Information on Dosage

FORTESTA family patents

Family Patents

4. Natesto patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8877230 ACERUS Controlled release delivery system for nasal applications
Feb, 2024

(4 months ago)

US8784882 ACERUS Controlled release delivery system for nasal applications and method of treatment
Feb, 2024

(4 months ago)

US8574622 ACERUS Controlled release delivery system for nasal applications
Feb, 2024

(4 months ago)

US8784869 ACERUS Controlled release delivery system for nasal applications and methods of treatment
Feb, 2024

(4 months ago)

US11090312 ACERUS Methods of treating hypogonadism with transnasal testerosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
Mar, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 28, 2017

Market Authorisation Date: 28 May, 2014

Treatment: Nasal administration of a testosterone gel to a patient to treat the patient for a condition associated with a deficiency or absence of endogenous testosterone; A method of testosterone replacement th...

Dosage: GEL, METERED;NASAL

More Information on Dosage

NATESTO family patents

Family Patents

5. Striant patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6248358 AUXILIUM PHARMS LLC Bioadhesive progressive hydration tablets and methods of making and using the same
Aug, 2019

(4 years ago)

Market Authorisation Date: 19 June, 2003

Treatment: Method of delivering an active ingredient using a progressive hydration bioadhesive

Dosage: TABLET, EXTENDED RELEASE;BUCCAL

More Information on Dosage

STRIANT family patents

Family Patents

6. Testim patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8178518 AUXILIUM PHARMS LLC Pharmaceutical composition
Apr, 2023

(1 year, 1 month ago)

US7608605 AUXILIUM PHARMS LLC Pharmaceutical composition
Apr, 2023

(1 year, 1 month ago)

US7608606 AUXILIUM PHARMS LLC Pharmaceutical composition
Apr, 2023

(1 year, 1 month ago)

US8063029 AUXILIUM PHARMS LLC Pharmaceutical composition
Apr, 2023

(1 year, 1 month ago)

US7608609 AUXILIUM PHARMS LLC Pharmaceutical composition
Apr, 2023

(1 year, 1 month ago)

US7608607 AUXILIUM PHARMS LLC Pharmaceutical composition
Apr, 2023

(1 year, 1 month ago)

US7608608 AUXILIUM PHARMS LLC Pharmaceutical composition
Apr, 2023

(1 year, 1 month ago)

US7608610 AUXILIUM PHARMS LLC Pharmaceutical composition
Apr, 2023

(1 year, 1 month ago)

US7935690 AUXILIUM PHARMS LLC Pharmaceutical composition
Apr, 2023

(1 year, 1 month ago)

US7320968 AUXILIUM PHARMS LLC Pharmaceutical composition
Jan, 2025

(7 months from now)

Market Authorisation Date: 31 October, 2002

Treatment: Method for administration of testosterone

Dosage: GEL;TRANSDERMAL

How can I launch a generic of TESTIM before it's drug patent expiration?
More Information on Dosage

TESTIM family patents

Family Patents

7. Testoderm patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5840327 ALZA Transdermal drug delivery device having enhanced adhesion
Aug, 2016

(7 years ago)

Market Authorisation Date: 12 October, 1993

Treatment: NA

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

More Information on Dosage

TESTODERM family patents

Family Patents

8. Testoderm Tts patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6348210 ALZA Methods for transdermal drug administration
Nov, 2019

(4 years ago)

Market Authorisation Date: 18 December, 1997

Treatment: Method for transdermal administration of a drug through non-scrotal skin using a transdermal drug delivery device containing the drug and having an adhesive surface

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

More Information on Dosage

TESTODERM TTS family patents

Family Patents

9. Vogelxo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9622340 UPSHER SMITH LABS Flexible circuit board and method for manufacturing same
Feb, 2034

(9 years from now)

US9295675 UPSHER SMITH LABS Testosterone gel compositions and related methods
Feb, 2034

(9 years from now)

US9662340 UPSHER SMITH LABS Testosterone gel compositions and related methods
Feb, 2034

(9 years from now)

US8785426 UPSHER SMITH LABS Testosterone gel compositions and related methods
Feb, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 04, 2017

Market Authorisation Date: 04 June, 2014

Treatment: Method for transdermal delivery of testosterone

Dosage: GEL;TRANSDERMAL; GEL, METERED;TRANSDERMAL

More Information on Dosage

VOGELXO family patents

Family Patents